Zota Health Care LImited — Important, 09-12-2024: Updates

Zota Health Care Limited has received product registration licenses for twelve pharmaceutical products from the Department of Pharmaceutical Administration in Vietnam, covering categories like angiotensin II antagonists, NSAIDs, antibiotics, and antihyperlipidemics. The licenses valid for five years can be renewed upon expiration. The company is set to commence exports of these products to Vietnam in the near term, marking a significant opportunity for growth in the international market. This move is expected to enhance Zota's product portfolio and revenue streams, presenting a positive outlook for shareholders as the company expands its footprint in Southeast Asia. Investors should watch closely for updates on export activities and market reception.